Summary:
A study of the safety, tolerability, and pharmacokinetics of kd-247, a humanized monoclonal antibody that recognizes the principal neutralizing determinant of hiv-1, in asymptomatic hiv-1 seropositive individuals who are not receiving concurrent antiretroviral therapy.
Qualified Participants Must:
• Have HIV-1 infection
•
Be 18-64 years of age
•
Have not been treated with, or have been off antiretroviral drugs for at least 8 weeks prior to screening
•
Have not been receiving treatment for any opportunistic infection
•
Weigh 45-120 kg
•
If female subjects must be:
•
Women of non-childbearing potential, defined as either surgically sterile or at least 2-years post-menopausal, or
•
Women of childbearing potential using a highly effective method of contraception
•
Be willing and able to provide written informed consent